Tag: Seroquel

What my doctor had told me would be a two-week withdrawal from Seroquel turned into a 14-month nightmare with lasting repercussions: the movement disorder tardive dyskinesia.

From NPR: "...researchers have conducted an experiment that convinced some of the general practice doctors who prescribe Seroquel most frequently to cut back. All the...

From The Washington Post: Despite major lawsuits and detailed reports pertaining to severe health risks associated with the antipsychotic Seroquel, the drug remains one of...

From the Chicago Tribune: Former drug sales representative Allison Zayas became a whistleblower against her old company, AstraZeneca, after learning that a combination of Seroquel...

From National Post: Many physicians are prescribing a low dose of Seroquel, an atypical antipsychotic, to patients with insomnia. Experts warn that even a low...

As a psychiatric survivor who has personally experienced severe psychosis, my criticisms focus on the relative lack of attention to what psychiatric drugs actually are, and on the uncertain, contested nature of the supposed target of these drugs: “schizophrenia.” I will elaborate on each of these points with references, as well as highlighting alternative approaches to helping psychotic people.

I have hopes for the field of psychiatry. I hope the field will redeem itself, and redeem its practitioners, because they do have clinical skill and the opportunity to learn more and grow. Many of them, I believe, were just taught bad science, influenced and infiltrated by Big Pharma.

Here I was, 15 years old and already in a long-term treatment facility. I was, on paper: crazy! This entire time, all the adults in my life had been speaking for me. I never felt like I was any of the things they said, but I went along with it. What else could I have done? Every time I rebelled, it only confirmed to my mother what she thought of me.

A former pharma executive has broken ranks with the industry in a new book by reporting how multiple psychiatrists, schools, and his desperate hopes pressed him to allow higher and higher doses of antipsychotic medications. The result: his 15-year-old son's death from Seroquel.

The New York Times reports that a growing number of infants and toddlers are being prescribed dangerous psychiatric drugs. “Almost 20,000 prescriptions for risperidone (commonly known as Risperdal), quetiapine (Seroquel) and other antipsychotic medications were written in 2014 for children 2 and younger, a 50 percent jump from 13,000 just one year before.”

Martha Rosenberg highlights how the popular antipsychotic Seroquel is a perfect example of how direct-to-consumer advertising made billion dollar blockbuster drugs possible before side-effects...

In 2004, the FDA added a black-box warning to SSRI antidepressants on the increased risk of suicide among children taking these drugs. A new study suggests that this warning has increased the proportion of children who begin an antidepressant on a low dose, but the majority are still receiving higher than recommended doses.

For the USC Center for Health Journalism, Martha Rosenberg points out the absurdity of allowing industry funded doctors to teach classes to practitioners about psychiatric drugs. "What if the written road test drivers take were sponsored by BP or Shell and had marketing messages interspersed?"

New York Times columnist, Nicholas Kristof, relates the story of Andrew Francesco, a boy who began taking Ritalin at age five and died from complications with Seroquel when he was fifteen. His father, a former pharmaceutical industry executive, reveals the industry’s greed in his memoir “Overmedicated and Undertreated.” Now the industry is pushing for a first-amendment right to market its drugs for off-label uses.

The wait has been exhausting, but it is possible that a flicker of light may finally shine on the dark recent history of psychiatric research at the University of Minnesota. Given these upcoming investigations of psychiatric research at the University of Minnesota, the time is right to look back at some of the disturbing, unanswered questions that have emerged over the past several years.

Professor Leigh Turner of the University of Minnesota Center for Bioethics blasts the Board of Regents for ignoring psychiatric research abuse.

Patient advocates and bioethicists have launched a call-in campaign demanding action on psychiatric research abuse at the University of Minnesota.

I received the following question from a reader regarding the controversial CAFÉ – Comparisons of Atypicals in First Episode of Psychosis - study. (This was the study in which Dan Markingson committed suicide.) "It appears that there was no head-to-head with a control group taking a placebo pill. Nor was there a control group featuring 'old' types of 'antipsychotic'. If that was the case then it is very poor study . . . what on earth can you hope to show from the data?" I started to write a response, but the subject is complex, and my response became the following article.

Responding to a letter signed by 175 scholars asking for an inquiry into the death of Dan Markingson at the University of Minnesota, the Faculty Senate voted to investigate clinical research at the university. But the university president says the Markingson case will not be part of the investigation. What is he trying to hide?

For a scathing, 11-minute overview of the death of Dan Markingson at the University of Minnesota, and new allegations of coercion into psychiatric clinical trials, you can't do much better than this excellent investigative report by Jeff Baillon.

It took over twenty years for the state medical board to sanction a Minnesota psychiatrist who was responsible for the deaths and injuries of 46 patients. Today, in the Markingson case, it looks as if history is repeating itself. How many patients die while bureaucrats delay?

Dan Markingson was floridly psychotic and unable to give informed consent when University of Minnesota researchers coerced him into an industry-funded drug study. His mother, Mary Weiss, warned the researchers that Dan was in danger of killing himself, but she was ignored. Dan committed a violent suicide in 2004. Last week, after fighting the university and research regulators for nine years, Mary suffered a severe stroke. Her struggle for justice is in serious danger.

Psychiatrists at the University of Minnesota forced a young man into a profitable study of antipsychotic drugs over the objections of his mother, who desperately warned that his condition was deteriorating and that he was in danger of killing himself. On May 8, 2004, Mary Weiss' only son, Dan Markingson, committed suicide. A petition to the governor of Minnesota now asks for an investigation.

In early 2009, antipsychotic fraud was making headlines.  Eli Lilly had announced in January that it would plead guilty to charges that it had...

Ever since critics began asking questions about the death of Dan Markinson in a clinical trial at the University of Minnesota, the General Counsel for the university, Mark Rotenberg, has responded with a uniform message: the case has already been investigated many times, and no wrongdoing has ever been found. That's how Rotenberg responded to my article about the case in Mother Jones, and that's how he responded last week to the news that the Board of Social Work had issued a “corrective action” to the study coordinator for the clinical trial in which Markingson died.